Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.40 |
| ▸ | CYP19A1 known ✓ | P11511 | 1/20 | 0.35 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.34 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.34 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.34 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.34 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29865458 | 1.00 | TSHR (0.40) | TSHRGAANOTUMNPC1POLB | |
| SCHEMBL827060 | 0.98 | GAA (0.41) | TSHRGAANOTUMNPC1POLB | |
| SCHEMBL27819634 | 0.87 | TSHR (0.39) | TSHRGAANOTUMNPC1POLB | |
| SCHEMBL2008574 | 0.80 | GAA (0.46) | TSHRGAANOTUMNPC1POLB | |
| SCHEMBL30746425 | 0.80 | GAA (0.46) | TSHRGAANOTUMNPC1POLB | |
| SCHEMBL20772453 | 0.77 | KIF11 (0.41) | GAANPC1POLBSLC22A12L3MBTL1 | |
| SCHEMBL31358487 | 0.76 | GAA (0.41) | GAASLC22A12CYP3A4SMN1; SMN2KIF11 | |
| SCHEMBL11955155 | 0.76 | GAA (0.41) | GAASLC22A12CYP3A4SMN1; SMN2KIF11 | |
| SCHEMBL13373493 | 0.73 | KIF11 (0.38) | GAANPC1POLBSLC22A12L3MBTL1 | |
| SCHEMBL27158664 | 0.73 | TDO2 (0.39) | NPC1POLBSLC22A12L3MBTL1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114920756-B | Preparation method of glabridin | 沈阳化工研究院有限公司 | 2023-09-08 | — | — | CN | claimed |
| CN-114920756-A | Preparation method of glabridin | 沈阳化工研究院有限公司 | 2022-08-19 | — | — | CN | claimed |
| CN-114920756-B | Preparation method of glabridin | 沈阳化工研究院有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-116547275-A | IL-17A modulators | 赛诺菲 | 2023-08-04 | — | — | CN | disclosed |
| US-20230227427-A1 | IL-17A MODULATORS | SANOFI (FR) | 2023-07-20 | — | — | US | disclosed |
| EP-4157827-A1 | IL-17A MODULATORS | SANOFI (FR) | 2023-04-05 | — | — | EP | disclosed |
| CN-114920756-A | Preparation method of glabridin | 沈阳化工研究院有限公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2021239743-A1 | IL-17A MODULATORS | SANOFI (FR) | 2021-12-02 | — | — | WO | disclosed |
| CN-110627711-B | Preparation method of chloro-trifluoromethyl pyridine | 浙江省化工研究院有限公司 | 2021-02-05 | — | — | CN | disclosed |
| US-10675268-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | CENTREXION THERAPEUTICS CORPORATION (US) | 2020-06-09 | — | — | US | disclosed |
| CN-110627711-A | Preparation method of chloro-trifluoromethyl pyridine | 浙江省化工研究院有限公司 | 2019-12-31 | — | — | CN | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| EP-2415771-A1 | INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Kissei Pharmaceutical Co., Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120015972-A1 | INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20110230465-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| WO-2011032277-A1 | QUINAZOLINONE DERIVATIVES AS VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | WO | disclosed |
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2258697-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-12-08 | — | — | EP | disclosed |
| CN-101621998-A | Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group | JANSSEN PHARMACEUTICA NV | 2010-01-06 | — | — | CN | disclosed |
| US-20090312339-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312339-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP | CNR1, CNR2, GPR18 | GAA 2287/4885CYP19A1 860/4885HTR3E 169/4885 |
| US-20230227427-A1 | IL-17A MODULATORS | IL17A, IL2, IL15 | GAA 1427/4885CYP19A1 243/4885HTR3E 1815/4885 |
| US-20120015972-A1 | INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, INMT, PON1 | GAA 1001/4885CYP19A1 254/4885HTR3E 307/4885 |
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | F12, F2, C3AR1 | GAA 4696/4885CYP19A1 465/4885HTR3E 1870/4885 |
| US-10675268-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | SSTR4, SSTR3, SSTR1 | GAA 2645/4885CYP19A1 872/4885HTR3E 94/4885 |
| US-20110230465-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2E | GAA 1558/4885CYP19A1 2250/4885HTR3E 4329/4885 |
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | GAA 3227/4885CYP19A1 1588/4885HTR3E 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.